Skip to main content
icon for Wen wird Trump als nächsten FDA-Kommissar bekannt geben?
Politik·FDA

Wen wird Trump als nächsten FDA-Kommissar bekannt geben?

icon for Wen wird Trump als nächsten FDA-Kommissar bekannt geben?
Politik·FDA

Wen wird Trump als nächsten FDA-Kommissar bekannt geben?

Kyle Diamantas 43%

Stephen Hahn 7%

Sara Brenner 3.3%

Brett Giroir 3.0%

Polymarket
NEU

Kyle Diamantas 43%

Stephen Hahn 7%

Sara Brenner 3.3%

Brett Giroir 3.0%

Polymarket
NEU

Kyle Diamantas

$1,298 Vol.

50%

Stephen Hahn

$975 Vol.

7%

Brett Giroir

$1,510 Vol.

3%

Grace Graham

$1,842 Vol.

3%

Sara Brenner

$848 Vol.

3%

No announcement by December 31

$425 Vol.

1%

This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner. An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs. Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner. Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify. A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate. If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”. The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Recent developments, including FDA Commissioner Marty Makary’s resignation amid internal administration friction over regulatory decisions, have elevated Deputy Commissioner Kyle Diamantas to acting commissioner, positioning him as the clear frontrunner for a permanent nomination. President Trump publicly praised Diamantas as “a very talented person” in the announcement, reflecting his recent oversight of the agency’s food program and alignment with current priorities. Other contenders such as former commissioner Stephen Hahn and former acting commissioner Brett Giroir remain under consideration but trail significantly in trader assessments, as does Sara Brenner and policy official Grace Graham. With no permanent announcement expected by year-end viewed as highly unlikely, the market reflects consensus around Diamantas’ established insider role and the administration’s preference for a swift transition.

This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.

An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.

Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.

Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.

A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.

If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.

The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Volumen
$6,898
Enddatum
31. Dez. 2026
Markt eröffnet
May 12, 2026, 7:59 PM ET

Resolver

0x69c47De9D...
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner. An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs. Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner. Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify. A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate. If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”. The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner. An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs. Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner. Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify. A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate. If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”. The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Recent developments, including FDA Commissioner Marty Makary’s resignation amid internal administration friction over regulatory decisions, have elevated Deputy Commissioner Kyle Diamantas to acting commissioner, positioning him as the clear frontrunner for a permanent nomination. President Trump publicly praised Diamantas as “a very talented person” in the announcement, reflecting his recent oversight of the agency’s food program and alignment with current priorities. Other contenders such as former commissioner Stephen Hahn and former acting commissioner Brett Giroir remain under consideration but trail significantly in trader assessments, as does Sara Brenner and policy official Grace Graham. With no permanent announcement expected by year-end viewed as highly unlikely, the market reflects consensus around Diamantas’ established insider role and the administration’s preference for a swift transition.

This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.

An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.

Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.

Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.

A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.

If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.

The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Volumen
$6,898
Enddatum
31. Dez. 2026
Markt eröffnet
May 12, 2026, 7:59 PM ET

Resolver

0x69c47De9D...
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner. An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs. Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner. Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify. A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate. If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”. The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.

Vorsicht bei externen Links.

Häufig gestellte Fragen

„Wen wird Trump als nächsten FDA-Kommissar bekannt geben?" ist ein Prognosemarkt auf Polymarket mit 6 möglichen Ergebnissen, bei dem Händler Anteile auf Basis ihrer Einschätzung kaufen und verkaufen. Das aktuell führende Ergebnis ist „Kyle Diamantas" mit 50%, gefolgt von „Stephen Hahn" mit 7%. Die Preise spiegeln Echtzeit-Wahrscheinlichkeiten der Community wider. Ein Anteilspreis von 50¢ bedeutet, dass der Markt diesem Ergebnis eine Wahrscheinlichkeit von 50% zuweist. Diese Quoten ändern sich laufend, wenn Händler auf neue Entwicklungen reagieren. Anteile am richtigen Ergebnis können bei Marktauflösung für jeweils $1 eingelöst werden.

„Wen wird Trump als nächsten FDA-Kommissar bekannt geben?" ist ein neu erstellter Markt auf Polymarket, gestartet am May 13, 2026. Als früher Markt haben Sie die Gelegenheit, zu den ersten Händlern zu gehören, die die Quoten setzen und die ersten Preissignale des Marktes etablieren. Sie können diese Seite auch als Lesezeichen speichern, um Volumen und Handelsaktivität zu verfolgen, während der Markt an Fahrt gewinnt.

Um auf „Wen wird Trump als nächsten FDA-Kommissar bekannt geben?" zu handeln, durchsuchen Sie die 6 verfügbaren Ergebnisse auf dieser Seite. Jedes Ergebnis zeigt einen aktuellen Preis, der die implizierte Wahrscheinlichkeit des Marktes darstellt. Um eine Position einzunehmen, wählen Sie das Ergebnis, das Sie für am wahrscheinlichsten halten, wählen Sie „Ja" um dafür oder „Nein" um dagegen zu handeln, geben Sie Ihren Betrag ein und klicken Sie auf „Handeln". Liegt Ihr gewähltes Ergebnis bei Marktauflösung richtig, zahlen Ihre „Ja"-Anteile jeweils $1 aus. Liegt es falsch, zahlen sie $0. Sie können Ihre Anteile auch jederzeit vor der Auflösung verkaufen.

Der aktuelle Favorit für „Wen wird Trump als nächsten FDA-Kommissar bekannt geben?" ist „Kyle Diamantas" mit 50%, was bedeutet, dass der Markt diesem Ergebnis eine Wahrscheinlichkeit von 50% zuweist. Das nächstliegende Ergebnis ist „Stephen Hahn" mit 7%. Diese Quoten werden in Echtzeit aktualisiert, wenn Händler Anteile kaufen und verkaufen. Schauen Sie regelmäßig vorbei oder speichern Sie diese Seite als Lesezeichen.

Die Auflösungsregeln für „Wen wird Trump als nächsten FDA-Kommissar bekannt geben?" definieren genau, was passieren muss, damit jedes Ergebnis als Gewinner erklärt wird – einschließlich der offiziellen Datenquellen zur Bestimmung des Ergebnisses. Sie können die vollständigen Auflösungskriterien im Abschnitt „Regeln" auf dieser Seite über den Kommentaren einsehen. Wir empfehlen, die Regeln vor dem Handeln sorgfältig zu lesen, da sie die genauen Bedingungen, Sonderfälle und Quellen festlegen.